Posted in | News | Medical Optics

Clinical Data on ReVision Optics’ Raindrop Microscopic Hydrogel Inlay Published in Journal of Cataract Refractive Surgery

ReVision Optics, Inc. (RVO), a leader in implantable presbyopia-correcting corneal inlay technology, announces that clinical data on the company’s Raindrop® Near Vision Inlay was published in the peer-reviewed Journal of Cataract Refractive Surgery.

The Raindrop Inlay is a microscopic hydrogel inlay designed to improve near and intermediate vision, thus reducing the need for reading glasses.

The article titled, “Range of refractive independence and mechanism of action of a corneal shape–changing hydrogel inlay: results and theory,” authored by Roger F. Steinert, MD, et al., reviewed data from a multi-center, prospective study that evaluated the visual acuity of 188 subjects with presbyopia who received the Raindrop Inlay in their non-dominant eye.

Study data showed improved visual acuity across the 2.0 D preoperative refractive range and improvement in task performance, independent of age and preoperative manifest refraction spherical equivalent (MRSE). In the Raindrop Inlay eye, the mean postoperative visual acuities were 20/25 for near vision, 20/25 for intermediate vision and 20/32 for distance vision. Binocularly, the subjects were all 20/25 at distance. Near task performance was also significantly improved postoperatively in both good and dim light, compared with preoperative levels.

“The Raindrop Inlay produced good visual acuity and performance from distance through near vision independent of the subject’s preoperative refraction (between -0.5 D to +1.5 D) or presbyopic age,” said Dr. Steinert, Chair of Ophthalmology and Director of the Gavin Herbert Eye Institute in Irvine, Calif. and a Medical Monitor for the Raindrop Inlay US FDA trial. “The Raindrop Inlay reshapes the cornea creating a near center that transitions to intermediate and distance resulting in full range of vision. We confirmed the findings in this study using visual acuity simulations. We also were very impressed with the high rate of satisfaction experienced by the Raindrop Inlay study subjects.”

“These study data clearly add to the growing body of evidence supporting the efficacy of the Raindrop Inlay in improving the near and intermediate vision without significant compromise in distance vision in with people with presbyopia,” said John Kilcoyne, RVO President and Chief Executive Officer. “We associate the high satisfaction rate found in this study with what we call the ‘WOW factor’ whereby post procedure, the subjects were very quickly able to perform near tasks without having to hunt for reading glasses.”

Source: http://revisionoptics.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit
Azthena logo

AZoM.com powered by Azthena AI

Your AI Assistant finding answers from trusted AZoM content

Azthena logo with the word Azthena

Your AI Powered Scientific Assistant

Hi, I'm Azthena, you can trust me to find commercial scientific answers from AZoNetwork.com.

A few things you need to know before we start. Please read and accept to continue.

  • Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
  • Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
  • Large Language Models can make mistakes. Consider checking important information.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.